Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial
Posted inClinical Updates Wellness & Lifestyle

Impact of Structural Cardiac Abnormalities on the Efficacy and Safety of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: Insights from the PARAGLIDE-HF Trial

The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients with both abnormalities face higher hyperkalemia risk.